Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 5/20 | 0.39 |
| ▸ | PPP5C | P53041 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.33 |
| ▸ | PEPD | P12955 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3336695 | 1.00 | EPHX1 (0.42) | EPHX1GABRR1PPP5CSLC1A2SLC1A1 | |
| SCHEMBL6268386 | 0.90 | EPHX1 (0.53) | EPHX1GABRR1PPP5CSLC1A2SLC1A1 | |
| SCHEMBL241114 | 0.85 | EPHX1 (0.45) | EPHX1GABRR1SLC1A2SLC1A1GRM2 | |
| SCHEMBL20072852 | 0.85 | EPHX1 (0.45) | EPHX1GABRR1SLC1A2SLC1A1GRM2 | |
| SCHEMBL9805204 | 0.85 | EPHX1 (0.45) | EPHX1GABRR1SLC1A2SLC1A1GRM2 | |
| SCHEMBL14186720 | 0.85 | — | — | |
| SCHEMBL18553312 | 0.85 | — | — | |
| SCHEMBL14087178 | 0.85 | — | — | |
| SCHEMBL18375852 | 0.85 | — | — | |
| SCHEMBL301208 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606244-A2 | CYCLOALKYLAMIDES AND THEIR THERAPEUTIC USE AS ANTIEPILEPTIC AND ANTICONVULSANT | Abbott Laboratories (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20040209858-A1 | Cycloalkylamides and their therapeutic applications | ABBOTT LABORATORIES | 2004-10-21 | — | — | US | disclosed |
| WO-2004037769-A2 | CYCLOALKYLAMIDES AND THEIR THERAPEUTIC USE AS ANTIEPILEPTIC AND ANTICONVULSANT | ABBOTT LABORATORIES (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20040077618-A1 | Cycloalkylamides and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209858-A1 | Cycloalkylamides and their therapeutic applications | GAP43, SCN1B, GRIN2B | EPHX1 958/4885GABRR1 80/4885PPP5C 3183/4885 |
| US-20040077618-A1 | Cycloalkylamides and their therapeutic applications | GAP43, SCN1B, GRIN2B | EPHX1 958/4885GABRR1 80/4885PPP5C 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.